Literature DB >> 7952158

Thyroid peroxidase immunodetection as a tool to assist diagnosis of thyroid nodules on fine-needle aspiration biopsy.

C De Micco1, P Zoro, S Garcia, L Skoog, E M Tani, P Carayon, J F Henry.   

Abstract

In a previous work we have reported the presence in 96.9% of malignant and 4.2% of benign thyroid tumors of an immunological abnormality of the enzyme thyroid peroxidase, impeding the fixation of the anti-thyroid peroxidase monoclonal antibody termed "MoAb47". The present study has been designed to establish the ability of thyroid peroxidase immunodetection to assist the diagnosis of malignancy in fine-needle aspiration of thyroid nodules. The fixation of anti-thyroid peroxidase monoclonal antibody was investigated by immunohistochemistry on fine-needle aspirates of 150 surgically removed thyroid nodules (20 papillary carcinomas, five follicular carcinomas, 90 colloid adenomas, nine fetal adenoma, 13 atypical adenomas, five oncocytic adenomas, six Hashimoto's thyroiditis and two Graves' disease). The percentage of positive cells has been compared to the final histological diagnosis. In samples from 113/125 benign nodules 80-100% cells presented a positive immunoreaction, whereas all samples from malignant tumors yielded less than 80% positive cells. Benign nodules exhibiting less than 80% positive cells corresponded to three degenerative colloid nodules, five atypical follicular adenomas, two oncocytomas and two thyroiditis. According to results obtained in this series, with the value of 80% as the limit for discrimination between benign and high-risk nodules, the sensitivity of thyroid peroxidase staining for diagnosis of malignancy would be 100%, its specificity 90% and its overall accuracy 92%. Thyroid peroxidase staining with monoclonal antibody MoAb47 on fine-needle aspirates is a useful adjunct to conventional cytology for the investigation of patients with thyroid nodules.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7952158     DOI: 10.1530/eje.0.1310474

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

1.  Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors.

Authors:  Svetlana Savin; Dubravka Cvejic; Tijana Isic; Ivana Petrovic; Ivan Paunovic; Svetislav Tatic; Marija Havelka
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

Review 2.  Molecular diagnostic tests in the diagnosis and management of thyroid carcinoma.

Authors:  M D Ringel
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

3.  Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.

Authors:  E Saggiorato; S Aversa; D Deandreis; F Arecco; A Mussa; B Puligheddu; S Cappia; S Conticello; M Papotti; F Orlandi
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

4.  Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV.

Authors:  C de Micco; V Savchenko; R Giorgi; F Sebag; J-F Henry
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

5.  Is there loss or qualitative changes in the expression of thyroid peroxidase protein in thyroid epithelial cancer?

Authors:  B Czarnocka; D Pastuszko; M Janota-Bzowski; A P Weetman; P F Watson; E H Kemp; R S McIntosh; M S Asghar; B Jarzab; E Gubala; J Wloch; D Lange
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

6.  Cytomorphological Spectrum of Thyroiditis: A Review of 110 Cases.

Authors:  Shirish S Chandanwale; Rahul Nair; Anushree Gambhir; Supreet Kaur; Aditi Pandey; Abhinav Shetty; Piyusha Naragude
Journal:  J Thyroid Res       Date:  2018-03-01

7.  A study of malignancy rates in different diagnostic categories of the Bethesda system for reporting thyroid cytopathology: An institutional experience.

Authors:  P Arul; C Akshatha; Suresh Masilamani
Journal:  Biomed J       Date:  2016-03-09       Impact factor: 4.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.